公开(公告)号：US10730952B2

公开(公告)日：2020-08-04

申请号：US15326499

申请日：2015-07-16

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright ,  Kerry Louise Tyson

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/18 ,  C07K16/46

Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

公开(公告)号：US10112996B2

公开(公告)日：2018-10-30

申请号：US15014145

申请日：2016-02-03

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/00 ,  A61K39/00

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

公开(公告)号：US09738710B2

公开(公告)日：2017-08-22

申请号：US14547291

申请日：2014-11-19

Applicant: UCB Biopharma SPRL

Inventor： Karen Margrete Miller ,  Marc Roger De Ryck ,  Christian Gilbert J. Wolff ,  Alastair David Griffiths Lawson ,  Helene Margaret Finney ,  Terence Seward Baker

IPC: A61K39/395 ,  C12P21/08 ,  C07K16/00 ,  C07K16/28 ,  A61K39/00 ,  C07K16/18

CPC classification number: C07K16/18 ,  C07K16/28 ,  C07K2317/34

Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

公开(公告)号：US11384148B2

公开(公告)日：2022-07-12

申请号：US16271086

申请日：2019-02-08

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: A61K39/395 ,  A61K39/40 ,  C07K16/28 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60 ,  A61K47/64 ,  C07K16/00 ,  A61K39/00

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US10590197B2

公开(公告)日：2020-03-17

申请号：US15743756

申请日：2016-07-15

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Kerry Louise Tyson ,  Michael John Wright

IPC: C07K16/28 ,  A61K39/00 ,  A01K67/027

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

公开(公告)号：US20150232553A1

公开(公告)日：2015-08-20

申请号：US14585406

申请日：2014-12-30

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。

公开(公告)号：US20150203571A1

公开(公告)日：2015-07-23

申请号：US14547291

申请日：2014-11-19

Applicant: UCB BIOPHARMA SPRL

Inventor： Karen Margrete Miller ,  Marc Roger De Ryck ,  Christian Gilbert J. Wolff ,  Alastair David Griffiths Lawson ,  Helene Margaret Finney ,  Terence Seward Baker

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K16/28 ,  C07K2317/34

Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 抗E1离子通道抗体或其结合片段，包含所述抗体的药物组合物，抗体及其组合物的使用，例如用于治疗/调节疼痛以及产生和制备所述抗体的方法。

公开(公告)号：US11220547B2

公开(公告)日：2022-01-11

申请号：US16299407

申请日：2019-03-12

Applicant: UCB BIOPHARMA SPRL

Inventor： Paul Alan Atherfold ,  Thomas Allen Ceska ,  Helene Margaret Finney ,  Lara Kevorkian ,  Kaushik Sarkar ,  Bryan John Smith ,  Kerry Louise Tyson

IPC: C07H21/02 ,  C07H21/04 ,  C12P21/06 ,  C12P21/04 ,  C12N5/00 ,  C12N5/16 ,  C12N1/20 ,  C07K16/28 ,  A61K47/60 ,  A61K47/68 ,  C07K16/00 ,  A61K39/00

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US20190248890A1

公开(公告)日：2019-08-15

申请号：US16271086

申请日：2019-02-08

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/64 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K47/60 ,  A61K47/643 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5047 ,  G01N33/564 ,  G01N33/6854 ,  G01N33/6857 ,  G01N33/6893 ,  G01N2333/70535 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/104 ,  G01N2800/24 ,  G01N2800/28

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US10273302B2

公开(公告)日：2019-04-30

申请号：US15036209

申请日：2014-11-12

Applicant: UCB BIOPHARMA SPRL

Inventor： Paul Alan Atherfold ,  Thomas Allen Ceska ,  Helene Margaret Finney ,  Lara Kevorkian ,  Kaushik Sarkar ,  Bryan John Smith ,  Kerry Louise Tyson

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40 ,  C07K16/28 ,  A61K47/60 ,  A61K47/68 ,  A61K39/00

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.